Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06387654
Status:
RECRUITING
Last Update Posted:
2024-05-09
First Post:
2024-03-28
Brief Title:
Clinico-biological Collection of Autoimmune Dysimmune or Auto-inflammatory Dermatological Diseases
Sponsor:
University Hospital Toulouse
Organization:
University Hospital Toulouse
Study Overview
Official Title:
Constitution of a Collection of Biological Samples With the Aim of Carrying Out Clinico-biological and Physiopathological Investigations of Autoimmune Dysimmune or Auto-inflammatory Dermatological Diseases
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TekAPo
Brief Summary:
The aim of this project is to start a biological and clinical collection of patients presenting autoimmune dysimmune or auto-inflammatory dermatological diseases This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical scientific and industrial communities for the identification of new therapeutic strategies
Detailed Description:
Autoimmune diseases include around a hundred different clinical entities which are for the most part rare pathologies but which in combination concern 5-8 of the adult population with a strong female predominance FAI²R the disease chain rare autoimmune and auto-inflammatory drugs fai2rorg The common denominator of all these diseases is based on the breakdown of self-tolerance which is the origin of self-reactivity and whose physiopathological mechanisms are still not fully understood which generates numerous cross-sectional or fundamental studies In addition to this complexity there are significant inter-individual variabilities which lead to the definition of subgroups of patients on the basis of the clinical-biological profile and or the response to treatments Consequently and in view of the need to establish the diagnosis early and then to propose the best treatment in the perspective of an individualized medicine the clinical biological and genetic characteristics of these subgroups of patients must be explored in order to improve diagnostic and therapeutic capacities
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None